By: Vicki Moore
In patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), a study evaluating administration of lisocabtagene maraleucel (liso-cel) on an outpatient basis reported favorable safety with this treatment approach. The study’s findings were reported in the journal Blood Advances. 1